Futibatinib, also known as LYTGOBI, is a targeted cancer therapy approved for the treatment of advanced cholangiocarcinoma. While this drug can be highly effective, it may also cause several adverse reactions that patients and healthcare providers should be aware of. Understanding these side effects and how to manage them is crucial for maintaining the quality of life during treatment.

Understanding the Adverse Reactions of Futibatinib (LYTGOBI)

Eye Toxicity: Retinal Pigment Epithelial Detachment (RPED)

Futibatinib has been associated with retinal pigment epithelial detachment (RPED), which can lead to symptoms such as blurred vision. In clinical trials involving 318 patients, 9% experienced RPED. To monitor and manage this risk, patients are advised to undergo a comprehensive eye examination, including optical coherence tomography (OCT) of the macula, before starting treatment. Follow-up exams should occur every two months for the first six months and then every three months thereafter. If visual symptoms develop, patients should be urgently referred to an ophthalmologist for evaluation and follow-up every three weeks until the medication is discontinued if necessary.

Hyperphosphatemia and Soft Tissue Mineralization

Another significant adverse reaction associated with Futibatinib is hyperphosphatemia, which can result in soft tissue mineralization, calcification, and vascular calcification. The increase in phosphate levels is a pharmacodynamic effect of the drug. Throughout the treatment period, patients should have their phosphate levels monitored regularly. When serum phosphate levels reach or exceed 5.5 mg/dL, patients should begin a low-phosphate diet and receive phosphate-lowering therapy. For serum phosphate levels above 7 mg/dL, more intensive phosphate management should be initiated, and the dosage of Futibatinib may need to be reduced, interrupted, or permanently discontinued based on the severity and duration of hyperphosphatemia.

Gastrointestinal and General Side Effects

Futibatinib can cause a range of gastrointestinal and general side effects, including nausea, vomiting, diarrhea, fatigue, and skin reactions. These side effects can vary in severity from mild to severe. Patients experiencing these symptoms should consult their healthcare provider for appropriate management strategies. Depending on the severity, doctors may recommend dietary changes, additional medications, or dose adjustments to alleviate discomfort and improve tolerability.

Using Futibatinib (LYTGOBI) Safely: Dosage and Monitoring

Recommended Dosage and Administration

The recommended dose of Futibatinib is 20 mg (five 4 mg tablets) taken orally once daily until disease progression or unacceptable toxicity occurs. Patients should take the medication at approximately the same time each day, with or without food. Tablets should be swallowed whole and not crushed, chewed, split, or dissolved. If a dose is missed by more than 12 hours or if vomiting occurs, patients should skip the missed dose and resume their regular dosing schedule with the next scheduled dose.

Monitoring and Dose Adjustments

To ensure the safe use of Futibatinib, regular monitoring is essential. This includes monthly complete blood cell counts (CBC) until platelet counts stabilize, followed by periodic monitoring of neutrophil counts. Liver function tests (LFTs), including alanine transaminase (ALT), aspartate transaminase (AST), and bilirubin, should also be performed monthly. Blood pressure should be monitored every two weeks until the dose stabilizes and then monthly thereafter.

Dose adjustments may be necessary based on individual patient safety and tolerability. For specific adverse reactions, such as RPED or hyperphosphatemia, treatment may need to be paused, reduced, or stopped. Patients should always consult their healthcare provider before making any changes to their medication regimen.

Pregnancy and Breastfeeding Considerations

Based on animal studies, Futibatinib can cause fetal harm or miscarriage when administered to pregnant women. There is no available data on its use in human pregnancy. Pregnant women should be informed of the potential risks to the fetus. In preclinical studies, Futibatinib caused fetal malformations, growth retardation, and embryofetal death in pregnant rats at maternal plasma exposures below those expected in humans at the clinical dose of 20 mg.

There is no information on the presence of Futibatinib or its metabolites in human breast milk, the effects on breastfed infants, or the impact on milk production. Due to the potential for serious adverse reactions in breastfed infants, women are advised to avoid breastfeeding during treatment and for one week after the last dose.

Drug Interactions and Storage

Drug Interactions

Futibatinib is a substrate of CYP3A and P-gp. Co-administration with dual P-gp and strong CYP3A inhibitors should be avoided as they can increase Futibatinib exposure and the risk of adverse reactions. Similarly, dual P-gp and strong CYP3A inducers should be avoided as they can reduce Futibatinib's effectiveness. If concomitant use is necessary, close monitoring and dose adjustments may be required to manage potential interactions.

Storage and Expiration

Futibatinib should be stored at room temperature (20-25°C). The medication has a shelf life of 24 months from the date of manufacture. Proper storage conditions are essential to maintain the drug's efficacy and safety.

Conclusion

While Futibatinib (LYTGOBI) offers significant therapeutic benefits for patients with advanced cholangiocarcinoma, it is important to be aware of and manage its potential adverse reactions. Regular monitoring, appropriate dose adjustments, and adherence to healthcare provider recommendations are key to ensuring safe and effective treatment. Patients should communicate openly with their healthcare team about any side effects or concerns to optimize their care and improve their quality of life during treatment.